$MIRM
Mirum Pharmaceuticals, Inc. Stock $mirm

$mirm Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024032289 Filed on March 15, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$69.22M	$69.55M	$186.4M
YoY Change	119.07%	149.24%	141.85%
Cost Of Revenue	$17.83M	$22.51M	$44.53M
YoY Change	258.1%	400.89%	259.86%
Gross Profit	$51.39M	$47.04M	$141.8M
YoY Change	93.07%	100.94%	119.28%
Gross Profit Margin	74.24%	67.64%	76.11%
Selling, General & Admin	$45.64M	$46.18M	$145.9M
YoY Change	51.02%	74.49%	63.79%
% of Gross Profit	88.8%	98.17%	102.84%
Research & Development	$32.22M	$30.94M	$102.6M
YoY Change	36.84%	-0.55%	-3.96%
% of Gross Profit	62.7%	65.76%	72.34%
Depreciation & Amortization	$5.664M	$5.494M	$10.83M
YoY Change	323.64%	357.45%	234.43%
% of Gross Profit	11.02%	11.68%	7.63%
Operating Expenses	$95.69M	$77.12M	$248.5M
YoY Change	62.89%	33.95%	19.3%
Operating Profit	-$26.47M	-$30.08M	-$106.6M
YoY Change	-2.5%	-11.96%	-18.73%
Interest Expense	$56.00K	-$2.849M	-$4.194M
YoY Change	-102.84%	84.76%	-62.61%
% of Operating Profit
Other Income/Expense, Net	$1.757M	-$3.061M	-$2.824M
YoY Change	-316.65%	420.58%	-873.7%
Pretax Income	-$24.66M	-$32.92M	-$159.9M
YoY Change	-17.62%	-9.28%	12.56%
Income Tax	$624.0K	$225.0K	$991.0K
% Of Pretax Income
Net Earnings	-$25.28M	-$33.15M	-$160.9M
YoY Change	-16.1%	-9.01%	18.6%
Net Earnings / Revenue	-36.52%	-47.66%	-86.33%
Basic Earnings Per Share	-$0.54		-$4.00
Diluted Earnings Per Share	-$0.54	-$0.66	-$3.94
COMMON SHARES
Basic Shares Outstanding	47.00M	46.61M	40.89M
Diluted Shares Outstanding	46.93M shares		40.89M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$302.8M	$286.3M	$286.3M
YoY Change	129.3%	88.72%	88.72%
Cash & Equivalents	$302.8M	$286.3M	$286.3M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$10.02M	$10.94M	$10.94M
YoY Change	11.46%	22.22%	22.22%
Inventory	$21.61M	$19.59M	$19.59M
Prepaid Expenses
Receivables	$55.00M	$67.97M	$67.97M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$389.5M	$384.8M	$384.8M
YoY Change	125.99%	102.3%	102.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$501.0K	$706.0K	$1.990M
YoY Change	-42.87%	-22.76%	-15.14%
Goodwill
YoY Change
Intangibles	$257.4M	$252.9M
YoY Change	346.21%	329.02%
Long-Term Investments
YoY Change
Other Assets	$3.873M	$6.155M	$6.155M
YoY Change	189.68%	345.37%	-93.93%
Total Long-Term Assets	$262.5M	$259.1M	$259.1M
YoY Change	62.84%	59.26%	59.26%
TOTAL ASSETS
Total Short-Term Assets	$389.5M	$384.8M	$384.8M
Total Long-Term Assets	$262.5M	$259.1M	$259.1M
Total Assets	$652.0M	$643.9M	$643.9M
YoY Change	95.47%	82.46%	82.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$15.98M	$7.416M	$7.416M
YoY Change	148.18%	-14.66%	-14.66%
Accrued Expenses	$89.57M	$77.16M	$77.16M
YoY Change	121.71%	42.84%	40.42%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$105.9M	$85.68M	$85.68M
YoY Change	116.84%	32.37%	32.37%
LONG-TERM LIABILITIES
Long-Term Debt	$306.8M	$306.4M	$306.4M
YoY Change
Other Long-Term Liabilities	$4.287M	$617.0K	$617.0K
YoY Change	455.31%	-86.39%	-99.58%
Total Long-Term Liabilities	$4.287M	$307.0M	$307.0M
YoY Change	455.31%	6674.89%	110.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$105.9M	$85.68M	$85.68M
Total Long-Term Liabilities	$4.287M	$307.0M	$307.0M
Total Liabilities	$417.4M	$392.7M	$392.7M
YoY Change	116.95%	86.24%	86.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$581.5M	-$556.2M
YoY Change	37.47%	41.6%
Common Stock	$816.1M	$803.3M
YoY Change	44.71%	50.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$234.6M	$251.2M	$251.2M
YoY Change
Total Liabilities & Shareholders Equity	$652.0M	$643.9M	$643.9M
YoY Change	95.47%	82.46%	82.46%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$25.28M	-$33.15M	-$160.9M
YoY Change	-16.1%	-9.01%	18.6%
Depreciation, Depletion And Amortization	$5.664M	$5.494M	$10.83M
YoY Change	323.64%	357.45%	234.43%
Cash From Operating Activities	$15.21M	-$16.62M	-$70.94M
YoY Change	-145.04%	-51.51%	-40.95%
INVESTING ACTIVITIES
Capital Expenditures	$13.00K	$5.000M	$20.11M
YoY Change	-68.29%	1966.12%	7133.45%
Acquisitions			$212.8M
YoY Change
Other Investing Activities	$0.00	$3.000M	-$87.09M
YoY Change	-100.0%	-88.89%	-1191.64%
Cash From Investing Activities	-$13.00K	-$2.000M	-$107.2M
YoY Change	-100.03%	-107.47%	-1492.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.205M	1.777M	336.6M
YoY Change	-90.72%	-640.12%	208.56%
NET CHANGE
Cash From Operating Activities	$15.21M	-16.62M	-70.94M
Cash From Investing Activities	-$13.00K	-2.000M	-107.2M
Cash From Financing Activities	$1.205M	1.777M	336.6M
Net Change In Cash	$16.52M	-16.84M	158.5M
YoY Change	-22.88%	114.78%	-4848.46%
FREE CASH FLOW
Cash From Operating Activities	$15.21M	-$16.62M	-$70.94M
Capital Expenditures	$13.00K	$5.000M	$20.11M
Free Cash Flow	$15.20M	-$21.62M	-$91.05M
YoY Change	-144.95%	-37.36%	-24.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001759425
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#DerivativeLiabilitiesCurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38981
CY2023	dei	Entity Registrant Name EntityRegistrantName	Mirum Pharmaceuticals, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-1281555
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	950 Tower Lane, Suite 1050
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Foster City
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94404
CY2023	dei	City Area Code CityAreaCode	650
CY2023	dei	Local Phone Number LocalPhoneNumber	667-4085
CY2023	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	MIRM
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	830100000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47003329
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	San Mateo, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	286326000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28003000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	0
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	123716000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	67968000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23994000
CY2023Q4	us-gaap	Inventory Net InventoryNet	22312000
CY2022Q4	us-gaap	Inventory Net InventoryNet	5565000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10935000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8947000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	387541000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	190225000
CY2023Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	0
CY2022Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	100000000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	706000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	914000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1284000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1431000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	252925000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	58954000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4165000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1382000
CY2023Q4	us-gaap	Assets Assets	646621000
CY2022Q4	us-gaap	Assets Assets	352906000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7416000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8690000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	78544000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	54018000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1104000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	931000
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1090000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	87064000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	64729000
CY2023Q4	mirm	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	0
CY2022Q4	mirm	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	140351000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	617000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1257000
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	306421000
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3849000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4532000
CY2023Q4	us-gaap	Liabilities Liabilities	397951000
CY2022Q4	us-gaap	Liabilities Liabilities	210869000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46723143
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46723143
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36956345
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36956345
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	5000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	803260000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	535074000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-556239000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-392824000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1644000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-217000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	248670000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	142037000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	646621000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	352906000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	186374000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77062000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19138000
CY2023	mirm	Cost Of Sales1 CostOfSales1	47039000
CY2022	mirm	Cost Of Sales1 CostOfSales1	12374000
CY2021	mirm	Cost Of Sales1 CostOfSales1	1903000
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	102609000
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	106842000
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	131428000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	145880000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	89066000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	59220000
CY2023	us-gaap	Operating Expenses OperatingExpenses	295528000
CY2022	us-gaap	Operating Expenses OperatingExpenses	208282000
CY2021	us-gaap	Operating Expenses OperatingExpenses	192551000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-109154000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-131220000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-173413000
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	13735000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	3857000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	366000
CY2023	mirm	Other Nonoperating Interest Expense OtherNonoperatingInterestExpense	15105000
CY2022	mirm	Other Nonoperating Interest Expense OtherNonoperatingInterestExpense	15979000
CY2021	mirm	Other Nonoperating Interest Expense OtherNonoperatingInterestExpense	17590000
CY2023	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	0
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	-906000
CY2021	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	732000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-49076000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023	mirm	Gain On Sale Of Priority Review Voucher GainOnSaleOfPriorityReviewVoucher	0
CY2022	mirm	Gain On Sale Of Priority Review Voucher GainOnSaleOfPriorityReviewVoucher	0
CY2021	mirm	Gain On Sale Of Priority Review Voucher GainOnSaleOfPriorityReviewVoucher	108000000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2824000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	365000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-582000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-162424000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-142071000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-83951000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	991000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6406000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	37000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-163415000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-135665000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-83988000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.01
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.77
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.02
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.77
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40885124
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33839072
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30321722
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40885124
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33982493
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30321722
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-163415000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-135665000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-83988000
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	230000
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-194000
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-117000
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1631000
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	12000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-161554000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-135847000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-84106000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	172095000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23087000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-83988000
CY2021	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-118000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	120212000
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	15585000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27448000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-135665000
CY2022	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-182000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	142037000
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	5188000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35845000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-163415000
CY2023	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	1861000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	248670000
CY2023	us-gaap	Profit Loss ProfitLoss	-163415000
CY2022	us-gaap	Profit Loss ProfitLoss	-135665000
CY2021	us-gaap	Profit Loss ProfitLoss	-83988000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	35023000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	27007000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	23087000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10829000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3238000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	595000
CY2023	mirm	Non Cash Lease Expense NonCashLeaseExpense	620000
CY2022	mirm	Non Cash Lease Expense NonCashLeaseExpense	443000
CY2021	mirm	Non Cash Lease Expense NonCashLeaseExpense	380000
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1725000
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1703000
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	137000
CY2023	mirm	Non Cash Interest Expense On Revenue Interest Purchase Agreement NonCashInterestExpenseOnRevenueInterestPurchaseAgreement	5060000
CY2022	mirm	Non Cash Interest Expense On Revenue Interest Purchase Agreement NonCashInterestExpenseOnRevenueInterestPurchaseAgreement	15979000
CY2021	mirm	Non Cash Interest Expense On Revenue Interest Purchase Agreement NonCashInterestExpenseOnRevenueInterestPurchaseAgreement	17590000
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1117000
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements	906000
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements	-732000
CY2023	mirm	Change In Fair Value Of Contingent Liabilities Associated With Acquisition ChangeInFairValueOfContingentLiabilitiesAssociatedWithAcquisition	-671000
CY2022	mirm	Change In Fair Value Of Contingent Liabilities Associated With Acquisition ChangeInFairValueOfContingentLiabilitiesAssociatedWithAcquisition	899000
CY2021	mirm	Change In Fair Value Of Contingent Liabilities Associated With Acquisition ChangeInFairValueOfContingentLiabilitiesAssociatedWithAcquisition	0
CY2023	mirm	Inventory Reserves And Firm Purchase Commitment Losses Under Operating Activity InventoryReservesAndFirmPurchaseCommitmentLossesUnderOperatingActivity	-9257000
CY2022	mirm	Inventory Reserves And Firm Purchase Commitment Losses Under Operating Activity InventoryReservesAndFirmPurchaseCommitmentLossesUnderOperatingActivity	0
CY2021	mirm	Inventory Reserves And Firm Purchase Commitment Losses Under Operating Activity InventoryReservesAndFirmPurchaseCommitmentLossesUnderOperatingActivity	0
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-49076000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023	mirm	Costs Recognized On Sale Of Acquired Inventory CostsRecognizedOnSaleOfAcquiredInventory	3419000
CY2022	mirm	Costs Recognized On Sale Of Acquired Inventory CostsRecognizedOnSaleOfAcquiredInventory	0
CY2021	mirm	Costs Recognized On Sale Of Acquired Inventory CostsRecognizedOnSaleOfAcquiredInventory	0
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1764000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0
CY2023	mirm	Tax Benefit Associated With An Acquisition TaxBenefitAssociatedWithAnAcquisition	0
CY2022	mirm	Tax Benefit Associated With An Acquisition TaxBenefitAssociatedWithAnAcquisition	6580000
CY2021	mirm	Tax Benefit Associated With An Acquisition TaxBenefitAssociatedWithAnAcquisition	0
CY2023	mirm	Gain On Sale Of Priority Review Voucher Net GainOnSaleOfPriorityReviewVoucherNet	0
CY2022	mirm	Gain On Sale Of Priority Review Voucher Net GainOnSaleOfPriorityReviewVoucherNet	0
CY2021	mirm	Gain On Sale Of Priority Review Voucher Net GainOnSaleOfPriorityReviewVoucherNet	108000000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	43974000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	20727000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3600000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3676000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4009000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4393000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3448000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	495000
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	511000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	127000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	519000
CY2023	mirm	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	30778000
CY2022	mirm	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	7639000
CY2021	mirm	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	22655000
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-940000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-711000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-649000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-70944000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-120136000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-132758000
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	27329000
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	132322000
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	198029000
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	153000000
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	140300000
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	155600000
CY2023	mirm	Proceeds From Paydowns Of Investments ProceedsFromPaydownsOfInvestments	0
CY2022	mirm	Proceeds From Paydowns Of Investments ProceedsFromPaydownsOfInvestments	0
CY2021	mirm	Proceeds From Paydowns Of Investments ProceedsFromPaydownsOfInvestments	2000000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	109000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	278000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24000
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	212762000
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	20000000
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	19000000
CY2023	mirm	Proceeds From Sale Of Priority Review Voucher Net ProceedsFromSaleOfPriorityReviewVoucherNet	0
CY2022	mirm	Proceeds From Sale Of Priority Review Voucher Net ProceedsFromSaleOfPriorityReviewVoucherNet	0
CY2021	mirm	Proceeds From Sale Of Priority Review Voucher Net ProceedsFromSaleOfPriorityReviewVoucherNet	108000000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-107200000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7700000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	48547000
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	202204000
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14480000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21289000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	86078000
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	6914000
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	305304000
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	10470000
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	7272000
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2098000
CY2023	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	281000
CY2022	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0
CY2021	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0
CY2023	mirm	Repayment Of Revenue Interest RepaymentOfRevenueInterest	-195577000
CY2022	mirm	Repayment Of Revenue Interest RepaymentOfRevenueInterest	-5552000
CY2021	mirm	Repayment Of Revenue Interest RepaymentOfRevenueInterest	-121000
CY2023	mirm	Proceeds From Revenue Interest Liability ProceedsFromRevenueInterestLiability	0
CY2022	mirm	Proceeds From Revenue Interest Liability ProceedsFromRevenueInterestLiability	0
CY2021	mirm	Proceeds From Revenue Interest Liability ProceedsFromRevenueInterestLiability	64575000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	336600000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	109087000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	73466000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-133000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-1000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	158323000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3337000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10746000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	128003000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	131340000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	142086000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	286326000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	128003000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	131340000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1079000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	911000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	864000
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	125000
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0
CY2023	us-gaap	Interest Paid Net InterestPaidNet	6817000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0
CY2023	mirm	Inventory Purchases In Accrued Liabilities InventoryPurchasesInAccruedLiabilities	6076000
CY2022	mirm	Inventory Purchases In Accrued Liabilities InventoryPurchasesInAccruedLiabilities	163000
CY2021	mirm	Inventory Purchases In Accrued Liabilities InventoryPurchasesInAccruedLiabilities	1018000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	473000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	285000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2023	mirm	Stock Based Compensation Capitalized To Inventory StockBasedCompensationCapitalizedToInventory	-822000
CY2022	mirm	Stock Based Compensation Capitalized To Inventory StockBasedCompensationCapitalizedToInventory	-441000
CY2021	mirm	Stock Based Compensation Capitalized To Inventory StockBasedCompensationCapitalizedToInventory	-71000
CY2023	mirm	Contingent Milestone And Indemnification Holdback Liability Connection With Settlement ContingentMilestoneAndIndemnificationHoldbackLiabilityConnectionWithSettlement	5188000
CY2022	mirm	Contingent Milestone And Indemnification Holdback Liability Connection With Settlement ContingentMilestoneAndIndemnificationHoldbackLiabilityConnectionWithSettlement	0
CY2021	mirm	Contingent Milestone And Indemnification Holdback Liability Connection With Settlement ContingentMilestoneAndIndemnificationHoldbackLiabilityConnectionWithSettlement	0
CY2023	mirm	Issuance Of Common Stock In Exchange For Acquired Intangible Assets IssuanceOfCommonStockInExchangeForAcquiredIntangibleAssets	0
CY2022	mirm	Issuance Of Common Stock In Exchange For Acquired Intangible Assets IssuanceOfCommonStockInExchangeForAcquiredIntangibleAssets	15585000
CY2021	mirm	Issuance Of Common Stock In Exchange For Acquired Intangible Assets IssuanceOfCommonStockInExchangeForAcquiredIntangibleAssets	0
CY2023	mirm	Accrued Milestone Payments Classified As Intangible Assets Net AccruedMilestonePaymentsClassifiedAsIntangibleAssetsNet	0
CY2022	mirm	Accrued Milestone Payments Classified As Intangible Assets Net AccruedMilestonePaymentsClassifiedAsIntangibleAssetsNet	15000000
CY2021	mirm	Accrued Milestone Payments Classified As Intangible Assets Net AccruedMilestonePaymentsClassifiedAsIntangibleAssetsNet	0
CY2023	mirm	Deferred Tax Liability Incurred From Acquired Intangible DeferredTaxLiabilityIncurredFromAcquiredIntangible	0
CY2022	mirm	Deferred Tax Liability Incurred From Acquired Intangible DeferredTaxLiabilityIncurredFromAcquiredIntangible	6580000
CY2021	mirm	Deferred Tax Liability Incurred From Acquired Intangible DeferredTaxLiabilityIncurredFromAcquiredIntangible	0
CY2023	mirm	Contingent Milestone Liability For Common Stock Issuance For Acquired Intangible Assets ContingentMilestoneLiabilityForCommonStockIssuanceForAcquiredIntangibleAssets	0
CY2022	mirm	Contingent Milestone Liability For Common Stock Issuance For Acquired Intangible Assets ContingentMilestoneLiabilityForCommonStockIssuanceForAcquiredIntangibleAssets	4600000
CY2021	mirm	Contingent Milestone Liability For Common Stock Issuance For Acquired Intangible Assets ContingentMilestoneLiabilityForCommonStockIssuanceForAcquiredIntangibleAssets	0
CY2023	mirm	Indemnification Holdback Liability In Exchange For Acquired Intangible Assets IndemnificationHoldbackLiabilityInExchangeForAcquiredIntangibleAssets	0
CY2022	mirm	Indemnification Holdback Liability In Exchange For Acquired Intangible Assets IndemnificationHoldbackLiabilityInExchangeForAcquiredIntangibleAssets	831000
CY2021	mirm	Indemnification Holdback Liability In Exchange For Acquired Intangible Assets IndemnificationHoldbackLiabilityInExchangeForAcquiredIntangibleAssets	0
CY2023	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2018-05-02
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-556200000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	286300000
CY2023Q4	mirm	Unrestricted Cash And Cash Equivalents UnrestrictedCashAndCashEquivalents	286300000
CY2023Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	305300000
CY2023Q2	mirm	Proceeds To Repurchase Future Revenue Interests ProceedsToRepurchaseFutureRevenueInterests	192700000
CY2023Q2	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	100000000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:4.28%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.28%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></p><p style="text-indent:4.28%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s consolidated financial statements as of and for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reflect the Company’s estimates of the impact of the geopolitical and macroeconomic environment, including the impact of inflation, bank failures, high interest rates and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company’s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the date of this filing.</span></p>
CY2022Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	100000000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	286326000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28003000
CY2023Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	0
CY2022Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	100000000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	286326000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	128003000
CY2023	mirm	Investments Classified As Cash And Cash Equivalent Original Maturities InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities	P3M
CY2023	mirm	Fair Value Of Its Investments Related To Credit Loss FairValueOfItsInvestmentsRelatedToCreditLoss	0
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0
CY2023Q4	mirm	Purchase Commitments PurchaseCommitments	5200000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1500000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1000000
CY2023	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	300000
CY2022	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	300000
CY2021	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	300000
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	266590000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13665000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	252925000
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P12Y3M18D
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	62107000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3153000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	58954000
CY2022Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y10M24D
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10500000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2900000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	21545000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	21545000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	21436000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	21221000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	21221000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	145957000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	252925000
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	186374000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77062000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19138000
CY2023	us-gaap	Advertising Expense AdvertisingExpense	6300000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	4000000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	9200000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1800000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-163415000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-135665000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-83988000
CY2023	mirm	Fair Value Adjustment Of Holdback Indemnification Liability FairValueAdjustmentOfHoldbackIndemnificationLiability	0
CY2022	mirm	Fair Value Adjustment Of Holdback Indemnification Liability FairValueAdjustmentOfHoldbackIndemnificationLiability	214000
CY2021	mirm	Fair Value Adjustment Of Holdback Indemnification Liability FairValueAdjustmentOfHoldbackIndemnificationLiability	0
CY2023	mirm	Fair Value Adjustment Of Contingent Milestone Liability FairValueAdjustmentOfContingentMilestoneLiability	0
CY2022	mirm	Fair Value Adjustment Of Contingent Milestone Liability FairValueAdjustmentOfContingentMilestoneLiability	700000
CY2021	mirm	Fair Value Adjustment Of Contingent Milestone Liability FairValueAdjustmentOfContingentMilestoneLiability	0
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-163415000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-136579000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-83988000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40885124
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33839072
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30321722
CY2023	mirm	Weighted Average Holdback Indemnification Shares Issuable WeightedAverageHoldbackIndemnificationSharesIssuable	0
CY2022	mirm	Weighted Average Holdback Indemnification Shares Issuable WeightedAverageHoldbackIndemnificationSharesIssuable	19590
CY2021	mirm	Weighted Average Holdback Indemnification Shares Issuable WeightedAverageHoldbackIndemnificationSharesIssuable	0
CY2023	mirm	Weighted Average Contingent Milestone Shares WeightedAverageContingentMilestoneShares	0
CY2022	mirm	Weighted Average Contingent Milestone Shares WeightedAverageContingentMilestoneShares	123831
CY2021	mirm	Weighted Average Contingent Milestone Shares WeightedAverageContingentMilestoneShares	0
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40885124
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33982493
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30321722
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.01
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.77
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.02
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.77
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20897132
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8981862
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7086136
CY2023Q4	mirm	Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis	278116000
CY2023Q4	mirm	Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2023Q4	mirm	Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0
CY2023Q4	mirm	Cash Equivalents And Available For Sale Securities Debt Securities CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities	278116000
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	278116000
CY2023Q4	mirm	Cash Equivalents And Available For Sale Securities Debt Securities CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities	278116000
CY2022Q4	mirm	Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis	248172000
CY2022Q4	mirm	Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2022Q4	mirm	Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	230000
CY2022Q4	mirm	Cash Equivalents And Available For Sale Securities Debt Securities CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities	247942000
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	24226000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	100000000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	123716000
CY2022Q4	mirm	Cash Equivalents And Available For Sale Securities Debt Securities CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities	247942000
CY2023	mirm	Available For Sale Securities Gross Realized Gain Loss Net1 AvailableForSaleSecuritiesGrossRealizedGainLossNet1	0
CY2022	mirm	Available For Sale Securities Gross Realized Gain Loss Net1 AvailableForSaleSecuritiesGrossRealizedGainLossNet1	0
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0
CY2023	mirm	Credit Losses On Available For Debt Securities CreditLossesOnAvailableForDebtSecurities	0
CY2022	mirm	Credit Losses On Available For Debt Securities CreditLossesOnAvailableForDebtSecurities	0
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	2998000
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	0
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	9873000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5351000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9441000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	214000
CY2023Q4	us-gaap	Inventory Net InventoryNet	22312000
CY2022Q4	us-gaap	Inventory Net InventoryNet	5565000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20939000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14660000
CY2023Q4	mirm	Accrued Sales Deductions Current AccruedSalesDeductionsCurrent	23650000
CY2022Q4	mirm	Accrued Sales Deductions Current AccruedSalesDeductionsCurrent	4284000
CY2023Q4	mirm	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	7268000
CY2022Q4	mirm	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	8319000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7941000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5372000
CY2023Q4	mirm	Accrued Manufacturing And Non Clinical Costs Current AccruedManufacturingAndNonClinicalCostsCurrent	9922000
CY2022Q4	mirm	Accrued Manufacturing And Non Clinical Costs Current AccruedManufacturingAndNonClinicalCostsCurrent	3927000
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	6716000
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2456000
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2108000
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0
CY2023Q4	mirm	Accrued Milestone Payments Current AccruedMilestonePaymentsCurrent	0
CY2022Q4	mirm	Accrued Milestone Payments Current AccruedMilestonePaymentsCurrent	15000000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	78544000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	54018000
CY2021Q4	mirm	Revenue Interest Liability RevenueInterestLiability	129923000
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1996000
CY2022	mirm	Interest Expense Accrued InterestExpenseAccrued	15979000
CY2022	mirm	Derivative Liability Accrued DerivativeLiabilityAccrued	0
CY2022	mirm	Revenue Interest Payments RevenueInterestPayments	-5551000
CY2022	mirm	Derivative Liability Payments DerivativeLiabilityPayments	0
CY2022	us-gaap	Interest Expense Interest Bearing Liability Increase Decrease InterestExpenseInterestBearingLiabilityIncreaseDecrease	0
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	-906000
CY2022Q4	mirm	Revenue Interest Liability RevenueInterestLiability	140351000
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1090000
CY2023	mirm	Interest Expense Accrued InterestExpenseAccrued	5060000
CY2023	mirm	Derivative Liability Accrued DerivativeLiabilityAccrued	0
CY2023	mirm	Revenue Interest Payments RevenueInterestPayments	-2883000
CY2023	mirm	Derivative Liability Payments DerivativeLiabilityPayments	0
CY2023	mirm	Revenue Interest Liability Settlement RevenueInterestLiabilitySettlement	-192694000
CY2023	mirm	Derivative Liability Settlement DerivativeLiabilitySettlement	0
CY2023	mirm	Gains Losses On Extinguishment Of Debt Revenue Interest Liability GainsLossesOnExtinguishmentOfDebtRevenueInterestLiability	50166000
CY2023	mirm	Gains Losses On Extinguishment Of Derivative Liability GainsLossesOnExtinguishmentOfDerivativeLiability	-1090000
CY2023Q4	mirm	Revenue Interest Liability RevenueInterestLiability	0
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	0
CY2023Q4	mirm	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	0
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0
	mirm	Stock Issued During Period Shares Indemnification Holdback Liability StockIssuedDuringPeriodSharesIndemnificationHoldbackLiability	31631
CY2019Q1	us-gaap	Area Of Land AreaOfLand	5600
CY2023	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	The lease term is approximately four years with an option to extend the term for one five-year term, which at the time was not reasonably assured of exercise and therefore, not included in the lease term.
CY2019Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P4Y
CY2019Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q1	mirm	Tenant Improvement Allowance TenantImprovementAllowance	400000
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1300000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1700000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1193000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	366000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	123000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	123000
CY2023Q4	mirm	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	61000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1866000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	145000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1721000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	800000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	800000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000
CY2023	us-gaap	Operating Lease Variable Lease Income OperatingLeaseVariableLeaseIncome	200000
CY2022	us-gaap	Operating Lease Variable Lease Income OperatingLeaseVariableLeaseIncome	200000
CY2020Q3	mirm	Maximum Amount Of Sale Covered In Shelf Registration Statement MaximumAmountOfSaleCoveredInShelfRegistrationStatement	300000000
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	24145170
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11941705
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35023000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27007000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23016000
CY2023	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	800000
CY2022	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	400000
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	100000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-164953000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-142661000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-84217000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	2529000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	590000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	266000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-162424000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-142071000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-83951000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	37000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	67000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	18000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	887000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	157000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	37000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	991000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	175000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	37000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-5503000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1078000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6581000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	991000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6406000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	37000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0357
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.074
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0132
CY2023	mirm	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.005
CY2022	mirm	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.0065
CY2021	mirm	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.017
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0013
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0093
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0002
CY2023	mirm	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	0
CY2022	mirm	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	-0.0299
CY2021	mirm	Effective Income Tax Rate Reconciliation Executive Compensation EffectiveIncomeTaxRateReconciliationExecutiveCompensation	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Gilti Percent EffectiveIncomeTaxRateReconciliationGiltiPercent	0.0169
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Gilti Percent EffectiveIncomeTaxRateReconciliationGiltiPercent	0.0143
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Gilti Percent EffectiveIncomeTaxRateReconciliationGiltiPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0191
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0496
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0772
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2477
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2285
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2841
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0061
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0451
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0005
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	40455000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	34522000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	38065000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	23569000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	30071000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	26747000
CY2023Q4	mirm	Deferred Tax Assets Interest Limitation Attributes DeferredTaxAssetsInterestLimitationAttributes	15814000
CY2022Q4	mirm	Deferred Tax Assets Interest Limitation Attributes DeferredTaxAssetsInterestLimitationAttributes	3127000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8419000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	6726000
CY2023Q4	mirm	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	4055000
CY2022Q4	mirm	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	4733000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3953000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3101000
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	2316000
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	426000
CY2023Q4	mirm	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	269000
CY2022Q4	mirm	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	460000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	143417000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	103411000
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	161000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	272000
CY2023Q4	mirm	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	37000
CY2022Q4	mirm	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	100000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	198000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	372000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	143219000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	103039000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	40200000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	32500000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	23900000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9254000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6399000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1200000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2855000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	10454000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	9254000
CY2023Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	0
CY2022Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	0
CY2023Q4	ecd	Trd Arr Ind Name TrdArrIndName	Christopher Peetz
CY2023Q4	ecd	Trd Arr Ind Title TrdArrIndTitle	Chief Executive Officer
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	true
CY2023Q4	ecd	Trd Arr Adoption Date TrdArrAdoptionDate	December 28, 2023
CY2023Q4	ecd	Trd Arr Securities Agg Avail Amt TrdArrSecuritiesAggAvailAmt	75000
CY2023Q4	mirm	Trd Arr Expiration Date TrdArrExpirationDate	December 28, 2025
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
R38.htm	Edgar Link	pending
0000950170-24-032289-index-headers.html	Edgar Link	pending
0000950170-24-032289-index.html	Edgar Link	pending
0000950170-24-032289.txt	Edgar Link	pending
0000950170-24-032289-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img69780980_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mirm-20231231.htm	Edgar Link	pending
mirm-20231231.xsd	Edgar Link	pending
mirm-ex10_16a.htm	Edgar Link	pending
mirm-ex10_17.htm	Edgar Link	pending
mirm-ex10_19.htm	Edgar Link	pending
mirm-ex10_4.htm	Edgar Link	pending
mirm-ex23_1.htm	Edgar Link	pending
mirm-ex31_1.htm	Edgar Link	pending
mirm-ex31_2.htm	Edgar Link	pending
mirm-ex32_1.htm	Edgar Link	pending
mirm-ex32_2.htm	Edgar Link	pending
mirm-ex4_3.htm	Edgar Link	pending
mirm-ex97_1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
mirm-20231231_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MIRM
Mirum Pharmaceuticals, Inc. Stock $mirm

2024 Q1 Form 10-K Financial Statement

#000095017024032289 Filed on March 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MIRM Mirum Pharmaceuticals, Inc. Stock $mirm

2024 Q1 Form 10-K Financial Statement

#000095017024032289 Filed on March 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MIRM
Mirum Pharmaceuticals, Inc. Stock $mirm